Anti-MCV (anti-mutated citrullinated vimentin) test

The mutated citrullinated vimentin (MCV) antibody test detects antibodies against citrullinated vimentin, a type of anti‑citrullinated protein antibody. It helps diagnose rheumatoid arthritis, especially early or seronegative cases, and can predict disease severity and joint erosion. MCV antibodies are more specific than rheumatoid factor and may aid prognosis and treatment decisions when interpreted alongside clinical findings and other tests.

Most laboratories report anti‑mutated citrullinated vimentin (anti‑MCV) as negative when below about 20 U/mL. Values roughly 20–30 U/mL are considered equivocal/borderline, and levels above ~30 U/mL are regarded as positive and may indicate rheumatoid arthritis. Exact cutoffs depend on the assay and lab, so interpret results using the lab’s reference range and clinical context.

MCV (mean corpuscular volume) measures the average red blood cell size. In rheumatoid arthritis it helps evaluate anaemia and medication effects: low MCV suggests iron deficiency, while high MCV commonly occurs with methotrexate or folate/B12 deficiency. Regular full blood counts and iron/folate/B12 tests monitor causes and guide treatment — discuss abnormal results and management with your clinician.

Anti‑CCP is highly specific for rheumatoid arthritis, often positive in seropositive and erosive RA, palindromic rheumatism and undifferentiated inflammatory arthritis that may evolve into RA. It can also be detected less commonly in juvenile idiopathic arthritis, psoriatic arthritis, Sjögren’s syndrome, systemic lupus erythematosus and occasionally with chronic infections (e.g., hepatitis C) causing false positives.

ANCAs are not typical for rheumatoid arthritis; they can be detected in a minority of RA patients (reported in roughly 5–20% depending on studies), more often p‑ANCA than c‑ANCA. ANCA positivity alone does not diagnose RA and usually prompts evaluation for ANCA‑associated vasculitis, drug effects, or overlap syndromes. Results must be interpreted with clinical findings and other serologic tests.

A high anti-CCP result strongly suggests rheumatoid arthritis and predicts greater risk of persistent, erosive joint disease. It isn’t diagnostic alone, so clinicians combine it with symptoms, exam, rheumatoid factor and imaging. High levels warrant rheumatology referral for early treatment (DMARDs), monitoring and joint-protective strategies to limit progression. Rarely, anti-CCP can appear before symptoms or with other conditions.